Immune Checkpoint Inhibitors Market Size, Share & Trends Analysis Report By Type (PD-1, PD-L1, CTLA-4), By Application (Lung Cancer, Breast Cancer, Melanoma), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 3 Business Days
Immune Checkpoint Inhibitors Market Growth & Trends
The global immune checkpoint inhibitors market size is anticipated to reach USD 154.25 billion by 2030 and is projected to grow at a CAGR of 17.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market growth is driven by increasing prevalence of cancer, and growing FDA approvals of immune checkpoint inhibitors. Moreover, increasing funding for advancing cancer immunotherapy coupled with rising R&D activities by research institutes and key operating players are further impelling market growth.
The rise in prevalence of multiple cancers and increase in need for appropriate treatment options are anticipated to drive market growth. For instance, according to the International Agency for Research on Cancer (IARC), over 20.7 million new cancer cases were expected in 2023.In addition, according to the Breast Cancer Statistics and Resources, about 2.3 million women were diagnosed with breast cancer across the globe in 2020. Moreover, increased awareness among healthcare providers and patients about the adverse effects of chemotherapy & radiation therapy is a primary factor influencing the growth of alternative therapeutics, such as immune checkpoint inhibitors.
Growing funding for cancer immunotherapy is anticipated to offer lucrative opportunities for the market in the near future. Government and key organizations engage constantly in activities intended at curbing cancer immunotherapy healthcare expenditure by encouraging R&D activities to advance cancer immunotherapy including immune checkpoint inhibitors. For instance, in July 2023, the Cancer Research Institute awarded about USD 28 million in grants to boost innovations in immunotherapy. Similarly, in July 2021, the Rankin government announced an investment of USD 18 million to improve cancer therapy including immune checkpoint inhibitors. Such initiatives are driving market growth.
However, the high cost associated and complications of immune checkpoint inhibitors in cancer therapy pose a significant challenge. Immune checkpoint inhibitors for cancer treatment can lead to immune-related adverse events. These complications include skin issues, gastrointestinal problems like colitis, endocrine dysfunctions, pulmonary inflammation, rheumatologic symptoms, nervous system and cardiac complications, and renal issues. Although ICIs show significant success against cancer, these side effects are anticipated to hamper market growth during the forecast period.
Immune Checkpoint Inhibitors Market Report Highlights
Immune Checkpoint Inhibitors Market Growth & Trends
The global immune checkpoint inhibitors market size is anticipated to reach USD 154.25 billion by 2030 and is projected to grow at a CAGR of 17.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market growth is driven by increasing prevalence of cancer, and growing FDA approvals of immune checkpoint inhibitors. Moreover, increasing funding for advancing cancer immunotherapy coupled with rising R&D activities by research institutes and key operating players are further impelling market growth.
The rise in prevalence of multiple cancers and increase in need for appropriate treatment options are anticipated to drive market growth. For instance, according to the International Agency for Research on Cancer (IARC), over 20.7 million new cancer cases were expected in 2023.In addition, according to the Breast Cancer Statistics and Resources, about 2.3 million women were diagnosed with breast cancer across the globe in 2020. Moreover, increased awareness among healthcare providers and patients about the adverse effects of chemotherapy & radiation therapy is a primary factor influencing the growth of alternative therapeutics, such as immune checkpoint inhibitors.
Growing funding for cancer immunotherapy is anticipated to offer lucrative opportunities for the market in the near future. Government and key organizations engage constantly in activities intended at curbing cancer immunotherapy healthcare expenditure by encouraging R&D activities to advance cancer immunotherapy including immune checkpoint inhibitors. For instance, in July 2023, the Cancer Research Institute awarded about USD 28 million in grants to boost innovations in immunotherapy. Similarly, in July 2021, the Rankin government announced an investment of USD 18 million to improve cancer therapy including immune checkpoint inhibitors. Such initiatives are driving market growth.
However, the high cost associated and complications of immune checkpoint inhibitors in cancer therapy pose a significant challenge. Immune checkpoint inhibitors for cancer treatment can lead to immune-related adverse events. These complications include skin issues, gastrointestinal problems like colitis, endocrine dysfunctions, pulmonary inflammation, rheumatologic symptoms, nervous system and cardiac complications, and renal issues. Although ICIs show significant success against cancer, these side effects are anticipated to hamper market growth during the forecast period.
Immune Checkpoint Inhibitors Market Report Highlights
- Based on type, the PD-1 segment led the market with the largest revenue share of 73.3% in 2023, owing to growing R&D activities, increasing product approvals and surge in prescription of drugs such as pembrolizumab and nivolumab
- Based on application, the lung cancer segment held the market with the largest revenue share of 25.41% in 2023. Increase in number of lung cancer cases is a significant factor driving growth of this segment
- Based on application, the colorectal cancer segment is expected to grow at the fastest CAGR over forecast period
- Based on the distribution channel, the online pharmacy segment is expected to grow at the fastest CAGR over the forecast period, owing to the increasing accessibility and convenience of drug procurement
- North America dominated the market with the revenue share of 62.81% in 2023, owing to factors such as increasing prevalence of cancer, high purchasing power parity, government support for quality healthcare, and availability of reimbursement
- In March 2023, BioNTech, entered into strategic collaboration with OncoC4 to co-develop and commercialize new immune checkpoint inhibitor anti-CTLA-4 monoclonal antibody candidate for multiple solid tumor indications.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Application
1.2.3. End Use
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in Asia Pacific
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type outlook
2.2.2. Application outlook
2.2.3. End Use outlook
2.2.4. Regional outlook
2.3. Competitive Insights
CHAPTER 3. IMMUNE CHECKPOINT INHIBITORS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of cancer
3.2.1.2. Increasing R&D investments
3.2.1.3. Rise in healthcare spending
3.2.1.4. New product approvals and launches
3.2.2. Market restraint analysis
3.2.2.1. High cost of immune checkpoint inhibitors
3.3. Immune Checkpoint Inhibitors Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
3.3.4. Pipeline Analysis
CHAPTER 4. IMMUNE CHECKPOINT INHIBITORS MARKET: TYPE ESTIMATES & TREND ANALYSIS
4.1. Global Immune Checkpoint Inhibitors Market: Type Dashboard
4.2. Global Immune Checkpoint Inhibitors Market: Type Movement Analysis
4.3. Global Immune Checkpoint Inhibitors Market Estimates and Forecasts, by Type, Revenue (USD Million)
4.4. PD-1
4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. PD-L1
4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. CTLA-4
4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.7. Others
4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 5. IMMUNE CHECKPOINT INHIBITORS MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
5.1. Global Immune Checkpoint Inhibitors Market: Application Dashboard
5.2. Global Immune Checkpoint Inhibitors Market: Application Movement Analysis
5.3. Global Immune Checkpoint Inhibitors Market Estimates and Forecasts, by Application, Revenue (USD Million)
5.4. Lung Cancer
5.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Breast Cancer
5.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Bladder Cancer
5.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Melanoma
5.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.8. Cervical Cancer
5.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.9. Hodgkin Lymphoma Cancer
5.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.10. Colorectal Cancer
5.10.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.11. Others
5.11.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 6. IMMUNE CHECKPOINT INHIBITORS MARKET: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS
6.1. Global Immune Checkpoint Inhibitors Market: Distribution Channel Dashboard
6.2. Global Immune Checkpoint Inhibitors Market: Distribution Channel Movement Analysis
6.3. Global Immune Checkpoint Inhibitors Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
6.4. Hospital Pharmacies
6.4.1. Market estimates and forecasts, 2018 to 2030 (USD million)
6.5. Retail Pharmacies
6.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Online Pharmacies
6.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 7. IMMUNE CHECKPOINT INHIBITORS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Market Share Analysis, 2023 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.5. North America
7.5.1. U.S.
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.2. Canada
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
7.6. Europe
7.6.1. UK
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.2. Germany
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.3. France
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.4. Italy
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework/ reimbursement structure
7.6.4.3. Competitive scenario
7.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.5. Spain
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework/ reimbursement structure
7.6.5.3. Competitive scenario
7.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.6. Norway
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework/ reimbursement structure
7.6.6.3. Competitive scenario
7.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.7. Sweden
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework/ reimbursement structure
7.6.7.3. Competitive scenario
7.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.8. Denmark
7.6.8.1. Key country dynamics
7.6.8.2. Regulatory framework/ reimbursement structure
7.6.8.3. Competitive scenario
7.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
7.7. Asia Pacific
7.7.1. Japan
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.2. China
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.3. India
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.4. Australia
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.5. South Korea
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework/ reimbursement structure
7.7.5.3. Competitive scenario
7.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.6. Thailand
7.7.6.1. Key country dynamics
7.7.6.2. Regulatory framework/ reimbursement structure
7.7.6.3. Competitive scenario
7.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
7.8. Latin America
7.8.1. Brazil
7.8.1.1. Key country dynamics
7.8.1.2. Regulatory framework/ reimbursement structure
7.8.1.3. Competitive scenario
7.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
7.8.2. Mexico
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework/ reimbursement structure
7.8.2.3. Competitive scenario
7.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
7.8.3. Argentina
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework/ reimbursement structure
7.8.3.3. Competitive scenario
7.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
7.9. MEA
7.9.1. South Africa
7.9.1.1. Key country dynamics
7.9.1.2. Regulatory framework/ reimbursement structure
7.9.1.3. Competitive scenario
7.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
7.9.2. Saudi Arabia
7.9.2.1. Key country dynamics
7.9.2.2. Regulatory framework/ reimbursement structure
7.9.2.3. Competitive scenario
7.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
7.9.3. UAE
7.9.3.1. Key country dynamics
7.9.3.2. Regulatory framework/ reimbursement structure
7.9.3.3. Competitive scenario
7.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
7.9.4. Kuwait
7.9.4.1. Key country dynamics
7.9.4.2. Regulatory framework/ reimbursement structure
7.9.4.3. Competitive scenario
7.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. Sanofi
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. F. Hoffmann-La Roche Ltd.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Merck & Co.
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Bristol-Myers Squibb Company
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Eli Lilly and Company
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Regeneron Pharmaceuticals Inc.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. AstraZeneca PLC
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Shanghai Jhunsi Biosciences Ltd
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Immutep Ltd
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. BeiGene Ltd
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
8.3.14. GlaxoSmithKline PLC
8.3.14.1. Company overview
8.3.14.2. Financial performance
8.3.14.3. Product benchmarking
8.3.14.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Application
1.2.3. End Use
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in Asia Pacific
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type outlook
2.2.2. Application outlook
2.2.3. End Use outlook
2.2.4. Regional outlook
2.3. Competitive Insights
CHAPTER 3. IMMUNE CHECKPOINT INHIBITORS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of cancer
3.2.1.2. Increasing R&D investments
3.2.1.3. Rise in healthcare spending
3.2.1.4. New product approvals and launches
3.2.2. Market restraint analysis
3.2.2.1. High cost of immune checkpoint inhibitors
3.3. Immune Checkpoint Inhibitors Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
3.3.4. Pipeline Analysis
CHAPTER 4. IMMUNE CHECKPOINT INHIBITORS MARKET: TYPE ESTIMATES & TREND ANALYSIS
4.1. Global Immune Checkpoint Inhibitors Market: Type Dashboard
4.2. Global Immune Checkpoint Inhibitors Market: Type Movement Analysis
4.3. Global Immune Checkpoint Inhibitors Market Estimates and Forecasts, by Type, Revenue (USD Million)
4.4. PD-1
4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. PD-L1
4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. CTLA-4
4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.7. Others
4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 5. IMMUNE CHECKPOINT INHIBITORS MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
5.1. Global Immune Checkpoint Inhibitors Market: Application Dashboard
5.2. Global Immune Checkpoint Inhibitors Market: Application Movement Analysis
5.3. Global Immune Checkpoint Inhibitors Market Estimates and Forecasts, by Application, Revenue (USD Million)
5.4. Lung Cancer
5.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Breast Cancer
5.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Bladder Cancer
5.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Melanoma
5.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.8. Cervical Cancer
5.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.9. Hodgkin Lymphoma Cancer
5.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.10. Colorectal Cancer
5.10.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.11. Others
5.11.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 6. IMMUNE CHECKPOINT INHIBITORS MARKET: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS
6.1. Global Immune Checkpoint Inhibitors Market: Distribution Channel Dashboard
6.2. Global Immune Checkpoint Inhibitors Market: Distribution Channel Movement Analysis
6.3. Global Immune Checkpoint Inhibitors Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
6.4. Hospital Pharmacies
6.4.1. Market estimates and forecasts, 2018 to 2030 (USD million)
6.5. Retail Pharmacies
6.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Online Pharmacies
6.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 7. IMMUNE CHECKPOINT INHIBITORS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Market Share Analysis, 2023 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.5. North America
7.5.1. U.S.
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.2. Canada
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
7.6. Europe
7.6.1. UK
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.2. Germany
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.3. France
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.4. Italy
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework/ reimbursement structure
7.6.4.3. Competitive scenario
7.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.5. Spain
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework/ reimbursement structure
7.6.5.3. Competitive scenario
7.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.6. Norway
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework/ reimbursement structure
7.6.6.3. Competitive scenario
7.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.7. Sweden
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework/ reimbursement structure
7.6.7.3. Competitive scenario
7.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.8. Denmark
7.6.8.1. Key country dynamics
7.6.8.2. Regulatory framework/ reimbursement structure
7.6.8.3. Competitive scenario
7.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
7.7. Asia Pacific
7.7.1. Japan
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.2. China
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.3. India
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.4. Australia
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.5. South Korea
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework/ reimbursement structure
7.7.5.3. Competitive scenario
7.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.6. Thailand
7.7.6.1. Key country dynamics
7.7.6.2. Regulatory framework/ reimbursement structure
7.7.6.3. Competitive scenario
7.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
7.8. Latin America
7.8.1. Brazil
7.8.1.1. Key country dynamics
7.8.1.2. Regulatory framework/ reimbursement structure
7.8.1.3. Competitive scenario
7.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
7.8.2. Mexico
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework/ reimbursement structure
7.8.2.3. Competitive scenario
7.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
7.8.3. Argentina
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework/ reimbursement structure
7.8.3.3. Competitive scenario
7.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
7.9. MEA
7.9.1. South Africa
7.9.1.1. Key country dynamics
7.9.1.2. Regulatory framework/ reimbursement structure
7.9.1.3. Competitive scenario
7.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
7.9.2. Saudi Arabia
7.9.2.1. Key country dynamics
7.9.2.2. Regulatory framework/ reimbursement structure
7.9.2.3. Competitive scenario
7.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
7.9.3. UAE
7.9.3.1. Key country dynamics
7.9.3.2. Regulatory framework/ reimbursement structure
7.9.3.3. Competitive scenario
7.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
7.9.4. Kuwait
7.9.4.1. Key country dynamics
7.9.4.2. Regulatory framework/ reimbursement structure
7.9.4.3. Competitive scenario
7.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. Sanofi
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. F. Hoffmann-La Roche Ltd.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Merck & Co.
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Bristol-Myers Squibb Company
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Eli Lilly and Company
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Regeneron Pharmaceuticals Inc.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. AstraZeneca PLC
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Shanghai Jhunsi Biosciences Ltd
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Immutep Ltd
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. BeiGene Ltd
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
8.3.14. GlaxoSmithKline PLC
8.3.14.1. Company overview
8.3.14.2. Financial performance
8.3.14.3. Product benchmarking
8.3.14.4. Strategic initiatives
LIST OF TABLES
Table 1 List of abbreviation
Table 2 North America immune checkpoint inhibitors market, by region, 2018 - 2030 (USD Million)
Table 3 North America immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 4 North America immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 5 North America immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 6 U.S. immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 7 U.S. immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 8 U.S. immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 9 Canada immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 10 Canada immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 11 Canada immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 12 Europe immune checkpoint inhibitors market, by region, 2018 - 2030 (USD Million)
Table 13 Europe immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 14 Europe immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 15 Europe immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 16 Germany immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 17 Germany immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 18 Germany immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 19 U.K. immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 20 U.K. immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 21 U.K. immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 22 France immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 23 France immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 24 France immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 25 Italy immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 26 Italy immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 27 Italy immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 28 Spain immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 29 Spain immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 30 Spain immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 31 Denmark immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 32 Denmark immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 33 Denmark immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 34 Sweden immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 35 Sweden immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 36 Sweden immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 37 Norway immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 38 Norway immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 39 Norway immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 40 Asia Pacific immune checkpoint inhibitors market, by region, 2018 - 2030 (USD Million)
Table 41 Asia Pacific immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 42 Asia Pacific immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 43 Asia Pacific immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 44 China immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 45 China immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 46 China immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 47 Japan immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 48 Japan immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 49 Japan immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 50 India immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 51 India immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 52 India immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 53 South Korea immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 54 South Korea immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 55 South Korea immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 56 Australia immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 57 Australia immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 58 Australia immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 59 Thailand immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 60 Thailand immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 61 Thailand immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 62 Latin America immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 63 Latin America immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 64 Latin America immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 65 Brazil immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 66 Brazil immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 67 Brazil immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 68 Mexico immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 69 Mexico immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 70 Mexico immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 71 Argentina immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 72 Argentina immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 73 Argentina immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 74 MEA immune checkpoint inhibitors market, by region, 2018 - 2030 (USD Million)
Table 75 MEA immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 76 MEA immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 77 MEA immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 78 South Africa immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 79 South Africa immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 80 South Africa immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 81 Saudi Arabia immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 84 UAE immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 85 UAE immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 86 UAE immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 87 Kuwait immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 88 Kuwait immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 89 Kuwait immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 1 List of abbreviation
Table 2 North America immune checkpoint inhibitors market, by region, 2018 - 2030 (USD Million)
Table 3 North America immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 4 North America immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 5 North America immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 6 U.S. immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 7 U.S. immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 8 U.S. immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 9 Canada immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 10 Canada immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 11 Canada immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 12 Europe immune checkpoint inhibitors market, by region, 2018 - 2030 (USD Million)
Table 13 Europe immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 14 Europe immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 15 Europe immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 16 Germany immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 17 Germany immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 18 Germany immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 19 U.K. immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 20 U.K. immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 21 U.K. immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 22 France immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 23 France immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 24 France immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 25 Italy immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 26 Italy immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 27 Italy immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 28 Spain immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 29 Spain immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 30 Spain immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 31 Denmark immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 32 Denmark immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 33 Denmark immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 34 Sweden immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 35 Sweden immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 36 Sweden immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 37 Norway immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 38 Norway immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 39 Norway immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 40 Asia Pacific immune checkpoint inhibitors market, by region, 2018 - 2030 (USD Million)
Table 41 Asia Pacific immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 42 Asia Pacific immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 43 Asia Pacific immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 44 China immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 45 China immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 46 China immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 47 Japan immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 48 Japan immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 49 Japan immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 50 India immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 51 India immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 52 India immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 53 South Korea immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 54 South Korea immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 55 South Korea immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 56 Australia immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 57 Australia immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 58 Australia immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 59 Thailand immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 60 Thailand immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 61 Thailand immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 62 Latin America immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 63 Latin America immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 64 Latin America immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 65 Brazil immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 66 Brazil immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 67 Brazil immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 68 Mexico immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 69 Mexico immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 70 Mexico immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 71 Argentina immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 72 Argentina immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 73 Argentina immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 74 MEA immune checkpoint inhibitors market, by region, 2018 - 2030 (USD Million)
Table 75 MEA immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 76 MEA immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 77 MEA immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 78 South Africa immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 79 South Africa immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 80 South Africa immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 81 Saudi Arabia immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 84 UAE immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 85 UAE immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 86 UAE immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 87 Kuwait immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
Table 88 Kuwait immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
Table 89 Kuwait immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in APAC
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Immune checkpoint inhibitors market: market outlook
Fig. 10 Immune checkpoint inhibitors competitive insights
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration and growth prospect mapping
Fig. 14 Industry value chain analysis
Fig. 15 Immune checkpoint inhibitors market driver impact
Fig. 16 Immune checkpoint inhibitors market restraint impact
Fig. 17 Immune checkpoint inhibitors market strategic initiatives analysis
Fig. 18 Immune checkpoint inhibitors market: Type movement analysis
Fig. 19 Immune checkpoint inhibitors market: Type outlook and key takeaways
Fig. 20 PD-1 market estimates and forecast, 2018 - 2030
Fig. 21 PD-L1 estimates and forecast, 2018 - 2030
Fig. 22 CTLA-4 market estimates and forecast, 2018 - 2030
Fig. 23 Others estimates and forecast, 2018 - 2030
Fig. 24 Immune checkpoint inhibitors market: Application movement analysis
Fig. 25 Immune checkpoint inhibitors market: Application outlook and key takeaways
Fig. 26 Lung cancer market estimates and forecasts, 2018 - 2030
Fig. 27 Breast cancer market estimates and forecasts,2018 - 2030
Fig. 28 Bladder cancer market estimates and forecasts,2018 - 2030
Fig. 29 Melanoma market estimates and forecasts, 2018 - 2030
Fig. 30 Cervical cancer market estimates and forecasts,2018 - 2030
Fig. 31 Hodgkin lymphoma market estimates and forecasts,2018 - 2030
Fig. 32 Colorectal cancer market estimates and forecasts, 2018 - 2030
Fig. 33 Others market estimates and forecasts,2018 - 2030
Fig. 34 Immune checkpoint inhibitors market: Distribution channel movement analysis
Fig. 35 Immune checkpoint inhibitors market: Distribution channel outlook and key takeaways
Fig. 36 Hospital pharmacies market estimates and forecasts, 2018 - 2030
Fig. 37 Retail pharmacies market estimates and forecasts,2018 - 2030
Fig. 38 Online pharmacies market estimates and forecasts, 2018 - 2030
Fig. 39 Global immune checkpoint inhibitors market: Regional movement analysis
Fig. 40 Global immune checkpoint inhibitors market: Regional outlook and key takeaways
Fig. 41 Global immune checkpoint inhibitors market share and leading players
Fig. 42 North America market share and leading players
Fig. 43 Europe market share and leading players
Fig. 44 Asia Pacific market share and leading players
Fig. 45 Latin America market share and leading players
Fig. 46 Middle East & Africa market share and leading players
Fig. 47 North America, by country
Fig. 48 North America market estimates and forecasts, 2018 - 2030
Fig. 49 US market estimates and forecasts, 2018 - 2030
Fig. 50 Canada market estimates and forecasts, 2018 - 2030
Fig. 51 Europe market estimates and forecasts, 2018 - 2030
Fig. 52 UK market estimates and forecasts, 2018 - 2030
Fig. 53 Germany market estimates and forecasts, 2018 - 2030
Fig. 54 France market estimates and forecasts, 2018 - 2030
Fig. 55 Italy market estimates and forecasts, 2018 - 2030
Fig. 56 Spain market estimates and forecasts, 2018 - 2030
Fig. 57 Denmark market estimates and forecasts, 2018 - 2030
Fig. 58 Sweden market estimates and forecasts, 2018 - 2030
Fig. 59 Norway market estimates and forecasts, 2018 - 2030
Fig. 60 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 61 China market estimates and forecasts, 2018 - 2030
Fig. 62 Japan market estimates and forecasts, 2018 - 2030
Fig. 63 India market estimates and forecasts, 2018 - 2030
Fig. 64 Thailand market estimates and forecasts, 2018 - 2030
Fig. 65 South Korea market estimates and forecasts, 2018 - 2030
Fig. 66 Australia market estimates and forecasts, 2018 - 2030
Fig. 67 Latin America market estimates and forecasts, 2018 - 2030
Fig. 68 Brazil market estimates and forecasts, 2018 - 2030
Fig. 69 Mexico market estimates and forecasts, 2018 - 2030
Fig. 70 Argentina market estimates and forecasts, 2018 - 2030
Fig. 71 Middle East and Africa market estimates and forecasts, 2018 - 2030
Fig. 72 South Africa market estimates and forecasts, 2018 - 2030
Fig. 73 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 74 UAE market estimates and forecasts, 2018 - 2030
Fig. 75 Kuwait market estimates and forecasts, 2018 - 2030
Fig. 76 Market share of key market players - Immune checkpoint inhibitors market
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in APAC
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Immune checkpoint inhibitors market: market outlook
Fig. 10 Immune checkpoint inhibitors competitive insights
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration and growth prospect mapping
Fig. 14 Industry value chain analysis
Fig. 15 Immune checkpoint inhibitors market driver impact
Fig. 16 Immune checkpoint inhibitors market restraint impact
Fig. 17 Immune checkpoint inhibitors market strategic initiatives analysis
Fig. 18 Immune checkpoint inhibitors market: Type movement analysis
Fig. 19 Immune checkpoint inhibitors market: Type outlook and key takeaways
Fig. 20 PD-1 market estimates and forecast, 2018 - 2030
Fig. 21 PD-L1 estimates and forecast, 2018 - 2030
Fig. 22 CTLA-4 market estimates and forecast, 2018 - 2030
Fig. 23 Others estimates and forecast, 2018 - 2030
Fig. 24 Immune checkpoint inhibitors market: Application movement analysis
Fig. 25 Immune checkpoint inhibitors market: Application outlook and key takeaways
Fig. 26 Lung cancer market estimates and forecasts, 2018 - 2030
Fig. 27 Breast cancer market estimates and forecasts,2018 - 2030
Fig. 28 Bladder cancer market estimates and forecasts,2018 - 2030
Fig. 29 Melanoma market estimates and forecasts, 2018 - 2030
Fig. 30 Cervical cancer market estimates and forecasts,2018 - 2030
Fig. 31 Hodgkin lymphoma market estimates and forecasts,2018 - 2030
Fig. 32 Colorectal cancer market estimates and forecasts, 2018 - 2030
Fig. 33 Others market estimates and forecasts,2018 - 2030
Fig. 34 Immune checkpoint inhibitors market: Distribution channel movement analysis
Fig. 35 Immune checkpoint inhibitors market: Distribution channel outlook and key takeaways
Fig. 36 Hospital pharmacies market estimates and forecasts, 2018 - 2030
Fig. 37 Retail pharmacies market estimates and forecasts,2018 - 2030
Fig. 38 Online pharmacies market estimates and forecasts, 2018 - 2030
Fig. 39 Global immune checkpoint inhibitors market: Regional movement analysis
Fig. 40 Global immune checkpoint inhibitors market: Regional outlook and key takeaways
Fig. 41 Global immune checkpoint inhibitors market share and leading players
Fig. 42 North America market share and leading players
Fig. 43 Europe market share and leading players
Fig. 44 Asia Pacific market share and leading players
Fig. 45 Latin America market share and leading players
Fig. 46 Middle East & Africa market share and leading players
Fig. 47 North America, by country
Fig. 48 North America market estimates and forecasts, 2018 - 2030
Fig. 49 US market estimates and forecasts, 2018 - 2030
Fig. 50 Canada market estimates and forecasts, 2018 - 2030
Fig. 51 Europe market estimates and forecasts, 2018 - 2030
Fig. 52 UK market estimates and forecasts, 2018 - 2030
Fig. 53 Germany market estimates and forecasts, 2018 - 2030
Fig. 54 France market estimates and forecasts, 2018 - 2030
Fig. 55 Italy market estimates and forecasts, 2018 - 2030
Fig. 56 Spain market estimates and forecasts, 2018 - 2030
Fig. 57 Denmark market estimates and forecasts, 2018 - 2030
Fig. 58 Sweden market estimates and forecasts, 2018 - 2030
Fig. 59 Norway market estimates and forecasts, 2018 - 2030
Fig. 60 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 61 China market estimates and forecasts, 2018 - 2030
Fig. 62 Japan market estimates and forecasts, 2018 - 2030
Fig. 63 India market estimates and forecasts, 2018 - 2030
Fig. 64 Thailand market estimates and forecasts, 2018 - 2030
Fig. 65 South Korea market estimates and forecasts, 2018 - 2030
Fig. 66 Australia market estimates and forecasts, 2018 - 2030
Fig. 67 Latin America market estimates and forecasts, 2018 - 2030
Fig. 68 Brazil market estimates and forecasts, 2018 - 2030
Fig. 69 Mexico market estimates and forecasts, 2018 - 2030
Fig. 70 Argentina market estimates and forecasts, 2018 - 2030
Fig. 71 Middle East and Africa market estimates and forecasts, 2018 - 2030
Fig. 72 South Africa market estimates and forecasts, 2018 - 2030
Fig. 73 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 74 UAE market estimates and forecasts, 2018 - 2030
Fig. 75 Kuwait market estimates and forecasts, 2018 - 2030
Fig. 76 Market share of key market players - Immune checkpoint inhibitors market
